Toward broad-spectrum antiviral drugs for common cold and other infections

Toward broad-spectrum antiviral drugs for common cold and other infections

Scientists are reporting progress in the search for the first broad-spectrum drugs to combat human rhinoviruses (HRVs), which cause humanity's most common infectious diseases. Their study on these potential drugs for infections that include the common cold appears in the journal ACS Medicinal Chemistry Letters.

Angus MacLeod and colleagues note that although many HRV infections cause mild disease, they can lead to dangerous complications for millions of people with asthma and . Previous potential drugs for HRV either didn't work or caused unacceptable side effects, leaving only one potential drug still under development in clinical trials. MacLeod's team set out to find new antiviral candidates to meet this serious health challenge.

They describe identifying and successfully testing a group of compounds that work against , Coxsackie virus, poliovirus and enterovirus-71—the cause of hand, . The substances work by blocking the ability of these viruses to multiply.

More information: "Identification of a Series of Compounds with Potent Antiviral Activity for the Treatment of Enterovirus Infections" ACS Med. Chem. Lett., Article ASAP. DOI: 10.1021/ml400095m

add to favorites email to friend print save as pdf

Related Stories

Fighting drug-resistant flu viruses

Jul 15, 2009

Amid reports that swine flu viruses are developing the ability to shrug off existing antiviral drugs, scientists in Japan are reporting a first-of-its kind discovery that could foster a new genre of antivirals ...

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

Nov 26, 2014

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.